Tech World

US doubles spending on potential virus vaccine to nearly $1 billion

China Plus Published: 2020-07-27 10:46:04

The United States has doubled its investment — to nearly $1 billion — to expedite development of a potential COVID-19 vaccine by American firm Moderna, which on Monday begins the decisive final phase of clinical trials.

In this March 16, 2020 file photo, a subject receives a shot in the first-stage safety study clinical trial of a potential vaccine by Moderna for COVID-19, the disease caused by the new coronavirus, at the Kaiser Permanente Washington Health Research Institute in Seattle. [File photo: AP/Ted S. Warren]

In this March 16, 2020 file photo, a subject receives a shot in the first-stage safety study clinical trial of a potential vaccine by Moderna for COVID-19, the disease caused by the new coronavirus, at the Kaiser Permanente Washington Health Research Institute in Seattle. [File photo: AP/Ted S. Warren]

The government now plans to spend up to $472 million on top of the previously announced $483 million, the Moderna biotechnology company announced Sunday.

Moderna said the added investment was justified by its decision, in conjunction with the government, to “significantly” expand a Phase Three clinical trial of a candidate vaccine to include 30,000 participants.

In a small, initial trial, Moderna’s experimental vaccine produced coronavirus antibodies — which should help fend off the disease — in the bodies of all 45 participants.

In the expanded trial starting Monday, half the 30,000 participants will receive a 100-microgram dose of the vaccine, while the rest will be given a placebo.

The United States has suffered more than 146,000 coronavirus deaths, leading the world in that grim category, even as the number of new cases has continued to surge.

It has announced massive investments in a huge effort to expedite vaccine development and get millions of Americans vaccinated by early next year.

On Wednesday, the American-German BioNTech/Pfizer pharmaceutical alliance announced that the US government had committed $1.95 billion to procure 100 million doses of its eventual vaccine.

Moderna, which has been working with US health authorities, said it expects to be able to produce 500 million doses a year — and potentially up to 1 billion — starting in 2021.

Chinese biotech firm Sinovac said July 6 that it, too, would begin a Phase Three clinical trial “this month,” in collaboration with Brazil’s Butantan biologic research center.

Also reporting encouraging early results have been a British project developed by Oxford University in partnership with the multinational AstraZenica laboratory, and a Chinese project, led by researchers from agencies including the Academy of Military Medical Sciences.

That effort is being financed by the CanSino biotechnology group, which is listed on the Hong Kong stock exchange.

In all, nearly 200 candidate vaccines are in development, including 23 now in the clinical phase, being tested on humans.

(Story includes material sourced from AFP.)

Related posts

First dog to test positive for coronavirus in US dies: report

epoekie

Alexandria Ocasio-Cortez admonishes Republican lawmaker over sexist slur

epoekie

Smart speaker sales will eventually hit a wall – report

epoekie

Trump says closely monitoring Hurricane Hanna after landfall in Texas

epoekie

Double standards hinder counter-terrorism work

epoekie

China releases article exposing “U.S.-style human rights” crisis magnified by COVID-19

epoekie

Leave a Comment

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More